BioAge Labs Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
BIOA$5.69+6.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Unaudited Condensed Consolidated Balance Sheets
(in thousands, except share and per share information)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $334,474 | $21,644 |
| Restricted cash | — | 3,313 |
| Prepaid expenses and other current assets | 1,993 | 349 |
| Total current assets | 336,467 | 25,306 |
| Investments | 100 | 100 |
| Property and equipment, net | 543 | 323 |
| Operating right-of-use assets, net | 271 | 195 |
| Total assets | $337,381 | $25,924 |
| Liabilities | ||
| Current Liabilities: | ||
| Accounts payable | $2,098 | $1,866 |
| Accrued expenses and other current liabilities | 10,709 | 7,938 |
| Current portion of term loan | 6,000 | 6,000 |
| Operating lease liabilities, current | 273 | 194 |
| Convertible promissory notes | — | 20,674 |
| Convertible promissory notes embedded derivative liability | — | 18,183 |
| Deferred grant income | — | 3,313 |
| Total current liabilities | 19,080 | 58,168 |
| Term loan | 3,940 | 8,201 |
| Warrant liability | 613 | 229 |
| Total liabilities | 23,633 | 66,598 |
| Redeemable convertible preferred stock, par value of $0.00001, 31,634,362 shares authorized as of December 31, 2023, and 31,465,128 shares issued and outstanding as of December 31, 2023; aggregate liquidation preference of $131,864 as of December 31, 2023; no shares issued and outstanding as of September 30, 2024 | — | 132,722 |
| Commitments and Contingencies (Note 8) | ||
| Stockholders’ Equity (Deficit) | ||
| Common stock, $0.00001 par value; 500,000,000 and 52,400,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 34,196,821 and 1,673,314 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | — | — |
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized as of September 30, 2024; no shares issued and outstanding as of September 30, 2024; no shares authorized, issued, or outstanding as of December 31, 2023 | — | — |
| Additional paid-in-capital | 545,321 | 8,142 |
| Accumulated other comprehensive income | 109 | 164 |
| Accumulated deficit | (231,682) | (181,702) |
| Total stockholders’ equity (deficit) | 313,748 | (173,396) |
| Total liabilities and stockholders’ equity (deficit) | $337,381 | $25,924 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.